This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: DSM, JLL Join to Create Pharma Company

Tuesday's announcement comes a little more than a year after Patheon agreed to acquire Banner Pharmacaps, a niche maker of gelatin-based capsules, from Vion NV of the Netherlands, for an undisclosed amount. JLL's portfolio of healthcare companies also includes Wakefield, Mass.-based American Dental Partners, Medical Card Systems Inc., of Puerto Rico, and BioClinica, a Newtown, Penn.-based provider of clinical trial management services to pharmaceutical, biotechnology, medical device and contract research organizations worldwide.

The deal is expected to close in the first half of 2014.

DSM, of Heerlen, expects the deal to be accretive to earnings per share from 2014 onwards.

For advice on the deal DSM turned to JPMorgan and Latham & Watkins LLP, supported by Cleary Gottlieb Steen & Hamilton LLP, Norton Rose Fulbright Canada LLP, Allen & Overy LLP and Hinckley, Allen & Snyder LLP.

Morgan Stanley and Jefferies are serving as financial advisers to JLL Partners. Its legal advisers are Skadden, Arps, Slate, Meagher & Flom LLP, Borden Ladner Gervais LLP and Simpson Thacher & Bartlett LLP.

The independent directors at Patheon used BMO Capital Markets as independent valuation expert. RBC Capital Markets is the committee's financial adviser and its law firm is Blake, Cassels & Graydon LLP.

-- Written by Renee Cordes in New York

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $132.65 1.82%
FB $81.91 0.47%
GOOG $555.37 -1.71%
TSLA $231.55 6.01%
YHOO $44.36 -0.36%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs